Two distinct human myeloma cell lines originating from one patient with myeloma.
about
Illegitimate WNT signaling promotes proliferation of multiple myeloma cellsFGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expressionDeazaneplanocin a is a promising drug to kill multiple myeloma cells in their nicheEffect of the interaction between fibronectin and VLA-4 on the proliferation of human B cells, especially a novel human B-cell line, OPM-3Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.The natural pesticide dihydrorotenone induces human plasma cell apoptosis by triggering endoplasmic reticulum stress and activating p38 signaling pathway.Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.Retroviruses hijack chromatin loops to drive oncogene expression and highlight the chromatin architecture around proto-oncogenic loci.Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone DiseaseGene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoidsDiverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myelomaActivation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.CD48 as a novel molecular target for antibody therapy in multiple myeloma.Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro.Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions.SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.Analysis of surface antigen expression of human immunoglobulin-secreting cells: phenotypic heterogeneity in normal counterparts of myeloma cells.Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14.Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib.Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32).Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization.A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens.The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion.Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells
P2860
Q24568035-095BA5C9-E83A-42A9-899F-A960EB301FDEQ24804513-5CA57129-1473-4831-975F-5BBAB2189CC2Q28543228-AE211830-E569-48C4-AD85-DAC5E9221F91Q28647333-97EBB614-196A-4C72-8A35-2A0C238BB71EQ34490880-F20EE2C8-7A48-44AC-A32E-5ADA51F02EE4Q34904775-EF6ED9EC-711C-4306-AC41-00B0CAE330A4Q35126641-24F9007C-9FC2-43AE-8095-66A4860BE66BQ35584064-31280626-21EF-4847-81A2-2B13B59E30A8Q35938169-D626802A-67BF-4D55-AF42-016306610EEBQ36011988-386A2791-0DC2-4817-A4C7-0BD46E4B7A45Q36431877-66EB746F-77D0-475D-A4EC-C30AD460BBE4Q37148117-B7495DD0-ED31-4C69-A17E-90CF9A870186Q37197408-D0E403A5-BD02-4093-A2C1-654DF8F79A3EQ38436315-FDF3812C-C88C-4221-8F2F-8ECE10B940F7Q39440638-AB8CDA40-7780-4B3A-9377-FE20795ADA2DQ39508213-165102CC-9058-42F2-A69C-228815FE04A8Q39916105-4D8A3D85-D82E-4E95-8A22-CDB576866B2DQ40440440-5DEA5C6A-760E-4B1A-9AA8-02528DBFA8DAQ41284793-851CD109-95F5-4444-B822-6BB8A7DF2CACQ41658719-C3931ACC-7DCA-4A72-AEC5-834182C65306Q41749914-5A3B154E-BD98-499C-A4FE-EC4F9E5BAD81Q41882913-A4215640-0A3B-4EF1-96BB-4C4858F4BFAAQ42138375-232BD185-54CF-40B0-891D-02A56D30EDCFQ42813868-1D3BCC33-6738-4EC0-B611-E3CB9209D5A8Q46364364-446C79DC-AE9E-4AB1-8F3E-9BD0CF420986Q47555589-F8E4BF80-3EA6-418F-8885-50C930EA32EFQ47982958-02E2D106-1E33-4E6D-BE66-A819343F3F36Q53399607-2AC723E0-F880-4352-96D2-E708F5A82F24Q57309120-2B39CEE6-7B0A-4238-8E12-EDA997503B1D
P2860
Two distinct human myeloma cell lines originating from one patient with myeloma.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
Two distinct human myeloma cell lines originating from one patient with myeloma.
@en
Two distinct human myeloma cell lines originating from one patient with myeloma.
@nl
type
label
Two distinct human myeloma cell lines originating from one patient with myeloma.
@en
Two distinct human myeloma cell lines originating from one patient with myeloma.
@nl
prefLabel
Two distinct human myeloma cell lines originating from one patient with myeloma.
@en
Two distinct human myeloma cell lines originating from one patient with myeloma.
@nl
P2093
P356
P1476
Two distinct human myeloma cell lines originating from one patient with myeloma.
@en
P2093
S Katagiri
T Yonezawa
Y Kanayama
P304
P356
10.1002/IJC.2910360217
P577
1985-08-01T00:00:00Z